# A Study of AL8326 in Healthy Subjects

> **NCT07132957** · PHASE1 · COMPLETED · sponsor: **Advenchen Laboratories Nanjing Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Solid Tumors

## Interventions

- **DRUG:** 14C-labeled AL8326

## Key facts

- **NCT ID:** NCT07132957
- **Lead sponsor:** Advenchen Laboratories Nanjing Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-21
- **Primary completion:** 2025-05-17
- **Final completion:** 2025-05-17
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132957, "A Study of AL8326 in Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07132957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*